CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Prescribed drugs, Inc. (Nasdaq: ALNY), the main RNAi therapeutics firm, introduced immediately that administration will current an organization overview on the 43rd Nasdaq Digital Investor Convention on Friday, December 4, 2020 at 11:00 am ET.
A dwell audio webcast of the presentation can be out there on the Traders part of the Firm’s web site at www.alnylam.com/occasions. A replay can be out there on the Alnylam web site inside 48 hours after every occasion.
About Alnylam Prescribed drugs
Alnylam (Nasdaq: ALNY) is main the interpretation of RNA interference (RNAi) into a complete new class of modern medicines with the potential to rework the lives of individuals bothered with uncommon genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular illnesses. Primarily based on Nobel Prize-winning science, RNAi therapeutics signify a strong, clinically validated strategy for the therapy of a variety of extreme and debilitating illnesses. Based in 2002, Alnylam is delivering on a daring imaginative and prescient to show scientific chance into actuality, with a strong RNAi therapeutics platform. Alnylam’s industrial RNAi therapeutic merchandise are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran). Alnylam has a deep pipeline of investigational medicines, together with six product candidates which might be in late-stage growth. Alnylam is executing on its “Alnylam 2020” technique of constructing a multi-product, commercial-stage biopharmaceutical firm with a sustainable pipeline of RNAi-based medicines to deal with the wants of sufferers who’ve restricted or insufficient therapy choices. Alnylam is headquartered in Cambridge, MA. For extra details about our individuals, science and pipeline, please go to www.alnylam.com and have interaction with us on Twitter at @Alnylam or on LinkedIn.